Boden Guenther, Carnell Laura H
Division of Endocrinology/Diabetes/Metabolism and the General Clinical Research Center, Temple University School of Medicine, 3401 North Broad Street, Philadelphia, PA 19140, USA.
Best Pract Res Clin Endocrinol Metab. 2003 Sep;17(3):399-410. doi: 10.1016/s1521-690x(03)00032-0.
Obesity is commonly associated with elevated plasma levels of free fatty acids (FFAs). High levels of FFA have emerged as a major link between obesity and insulin resistance/type 2 diabetes (T2DM). Thus, acute and chronic elevations of plasma FFAs produce insulin resistance in skeletal muscle and liver. In skeletal muscle, FFA-induced insulin resistance is associated with accumulation of intramyocellular triglyceride and diacylglycerol, and with activation of protein kinase C (the beta and delta isoforms). It is suggested that FFAs interfere with insulin signalling via PKC-induced serine phosphorylation of the insulin receptor substrate-1. In the liver, FFAs cause insulin resistance by interfering with insulin suppression of glycogenolysis. In beta-cells, FFAs potentiate glucose-stimulated insulin secretion acutely and chronically. It is postulated that this prevents the development of T2DM in most (>80%) obese insulin-resistant people who have FFA-mediated insulin resistance. Elevated levels of FFA also seem to activate a pro-inflammatory and pro-atherogenic pathway (the IkappaB/NFkappaB pathway) and may be responsible, at least in part, for the increase in atherosclerotic vascular disease seen in patients with T2DM. As increased plasma levels account for up to 50% of insulin resistance in obese patients with T2DM, lowering of plasma FFAs could be a new and promising approach to the treatment of T2DM.
肥胖通常与血浆游离脂肪酸(FFA)水平升高有关。高水平的FFA已成为肥胖与胰岛素抵抗/2型糖尿病(T2DM)之间的主要联系。因此,血浆FFA的急性和慢性升高会在骨骼肌和肝脏中产生胰岛素抵抗。在骨骼肌中,FFA诱导的胰岛素抵抗与肌细胞内甘油三酯和二酰甘油的积累以及蛋白激酶C(β和δ亚型)的激活有关。有人认为,FFA通过PKC诱导的胰岛素受体底物-1的丝氨酸磷酸化来干扰胰岛素信号传导。在肝脏中,FFA通过干扰胰岛素对糖原分解的抑制作用而导致胰岛素抵抗。在β细胞中,FFA急性和慢性地增强葡萄糖刺激的胰岛素分泌。据推测,这可防止大多数(>80%)患有FFA介导的胰岛素抵抗的肥胖胰岛素抵抗人群发生T2DM。升高的FFA水平似乎还会激活促炎和促动脉粥样硬化途径(IkappaB/NFkappaB途径),并且可能至少部分地导致T2DM患者中动脉粥样硬化性血管疾病的增加。由于在患有T2DM的肥胖患者中,血浆水平升高占胰岛素抵抗的比例高达50%,降低血浆FFA可能是一种治疗T2DM的新的且有前景的方法。